← Back to Patent Explorer
US4368149A Expired / Lapsed US ⏱️ 0.0 years remaining

Protein hybrid having cytotoxicity and process for the preparation thereof

Assignee: Teijin Ltd
•
Filing: 1981-12-16
•
Granted: 1983-01-11
•
Expires: 2001-12-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A protein hybrid having cytotoxicity obtained by covalently bonding an immunoglobulin or its fragment, which is capable of binding selectively to an antigen possessed by a cell to be destroyed, to a protein, which is obtained from Momordica charantia and has an activity to terminate protein synthesis. This protein hybrid displays remarkable cytotoxicity against targel cells.

Inventors

  • 👤 Yasuhiko Masuho
  • 👤 Takeshi Hara

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 18:48
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6819; A61K47/6825; A61P; A61P35/00; A61P43/00; Y; Y10; Y10S; Y10S530/00; Y10S530/866

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 45 words
A protein hybrid having cytotoxicity prepared by covalently bonding an immunoglobulin, or its fragment, which is capable of binding selectively to an antigen produced by a cell to be killed, to a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis.
Claim 2
Dependent Claim 45 words
A protein hybrid having cytotoxicity prepared by covalently bonding an immunoglobulin, or its fragment, which is capable of binding selectively to an antigen produced by a cell to be killed, to a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis.
Claim 3
Dependent Claim 70 words
A protein hybrid having cytotoxicity according to claim 1, which is expressed by the following formula (I) or (II): Ab--(X.sub.1).sub.t --MOM).sub.n (I) (Ab--(X.sub.1).sub.t).sub.n MOM (II) where Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; X 1 is a divalent organic group; t indicates 0 or 1; and n represents an integer of 1 to 3.
Claim 4
Dependent Claim 106 words
A protein hybrid having cytotoxicity according to claim 1 or 2, which is expressed by the following formula (III) or (IV): Ab--(X.sub.2).sub.p --S.sub.1 --(X.sub.3).sub.q --S.sub.2 --X.sub.4 --MOM).sub.n (III) (Ab--(X.sub.2).sub.p --S.sub.1 --(X.sub.3).sub.q --S.sub.2 --X.sub.4).sub.n MOM (IV) where Ab indicates an immunoglobulin or its fragment, MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n represents an integer of 1 to 3; X 2 , X 3 and X 4 indicate a divalent organic group respectively; S 1 and S 2 indicate a sulfur atom respectively; and p and q are either the same or different and represent 0 or 1.
Claim 5
Dependent Claim 81 words
A protein hybrid having cytotoxicity according to claim 1 or 2, which is expressed by the following formula (V) or (VI): ##STR24## where Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n represents an interger of 1 to 3; X 2 indicates a divalent organic group; S 1 indicates a sulfur atom; and p is 0 or 1; and X 5 indicates a divalent organic group.
Claim 6
Dependent Claim 141 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (III-1) or (IV-1): Ab--(X.sub.2).sub.p --S.sub.1 --S.sub.2 --X.sub.4 --MOM).sub.n (III- 1) (Ab--(X.sub.2).sub.p --S.sub.1 --S.sub.2 --X.sub.4).sub.n MOM (IV-1) where Ab indicates an immunogloublin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n represents an integer of 1 to 3; X 2 and X 4 indicate a divalent organic group, respectively; S 1 and S 2 indicate a sulfur atom respectively; and p represents 0 or 1; comprising reacting a disulfide group, which is introduced into one of the protein of an immunoglobulin or its fragment and the protein which is obtained from Momordica charantia and is capable of inhibiting protein synthesis with a thiol group which is either self-produced in or introduced into the other of said proteins.
Claim 7
Dependent Claim 141 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (III-1) or (IV-1): Ab--(X.sub.2).sub.p --S.sub.1 --S.sub.2 --X.sub.4 --MOM).sub.n (III- 1) (Ab--(X.sub.2).sub.p --S.sub.1 --S.sub.2 --X.sub.4).sub.n MOM (IV-1) where Ab indicates an immunogloublin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n represents an integer of 1 to 3; X 2 and X 4 indicate a divalent organic group, respectively; S 1 and S 2 indicate a sulfur atom respectively; and p represents 0 or 1; comprising reacting a disulfide group, which is introduced into one of the protein of an immunoglobulin or its fragment and the protein which is obtained from Momordica charantia and is capable of inhibiting protein synthesis with a thiol group which is either self-produced in or introduced into the other of said proteins.
Claim 8
Dependent Claim 147 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (III-2) or (IV-2): Ab--(X.sub.2).sub.p --S.sub.1 --X.sub.3 --S.sub.2 --X.sub.4 --MOM).sub.n (III- 2) Ab--(X.sub.2).sub.p --S.sub.1 --X.sub.3 --S.sub.2 --X.sub.4).sub.n MOM (IV-2) wherein Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n is an integer of 1 to 3; X 2 , X 3 and X 4 indicate a divalent organic group respectively; S 1 and S 2 indicate a sulfur atom respectively; and p is 0 or 1; comprising linking an immunoglobulin or its fragment, which has a thio group either self-produced therein or introduced thereto, with a protein, which is obtained from Momordica charantia, capable of inhibiting protein synthesis, and has a thiol group introduced thereto, using a cross-linking agent having two functional groups capable of reacting with thiol groups.
Claim 9
Dependent Claim 147 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (III-2) or (IV-2): Ab--(X.sub.2).sub.p --S.sub.1 --X.sub.3 --S.sub.2 --X.sub.4 --MOM).sub.n (III- 2) Ab--(X.sub.2).sub.p --S.sub.1 --X.sub.3 --S.sub.2 --X.sub.4).sub.n MOM (IV-2) wherein Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; n is an integer of 1 to 3; X 2 , X 3 and X 4 indicate a divalent organic group respectively; S 1 and S 2 indicate a sulfur atom respectively; and p is 0 or 1; comprising linking an immunoglobulin or its fragment, which has a thio group either self-produced therein or introduced thereto, with a protein, which is obtained from Momordica charantia, capable of inhibiting protein synthesis, and has a thiol group introduced thereto, using a cross-linking agent having two functional groups capable of reacting with thiol groups.
Claim 10
Dependent Claim 107 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (V) or (VI): ##STR25## where Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; X 2 indicates a divalent organic group; X 5 indicates a divalent organic group; S 1 indicates a sulfur atom; and p is 0 or 1; comprising reacting an immunoglobulin or its fragment having a thiol group either self produced therein or introduced thereto with a protein which is obtained from Momordica charantia, capable of inhibiting protein synthesis, and has a maleimide group introduced thereto.
Claim 11
Dependent Claim 107 words
A process for preparing a protein hybrid having cytotoxicity expressed by the following formula (V) or (VI): ##STR25## where Ab indicates an immunoglobulin or its fragment; MOM is a protein which is obtained from Momordica charantia and capable of inhibiting protein synthesis; X 2 indicates a divalent organic group; X 5 indicates a divalent organic group; S 1 indicates a sulfur atom; and p is 0 or 1; comprising reacting an immunoglobulin or its fragment having a thiol group either self produced therein or introduced thereto with a protein which is obtained from Momordica charantia, capable of inhibiting protein synthesis, and has a maleimide group introduced thereto.

References Cited (Backward Citations)

US4046722A Cited
US4093607A Cited
US4315851A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-01-10 1986-07-12 1987-01-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-01-10 1990-07-12 1991-01-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-01-10 1994-07-12 1995-01-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag